Comprehensive, practical guide to canine Bordetella: transmission, diagnosis, treatment, vaccines (intranasal vs injectable), isolation and prevention in multi-dog settings.

Quick Overview

• What it is: Bordetella bronchiseptica is a bacterial respiratory pathogen commonly involved in canine infectious respiratory disease complex (CIRDC; "kennel cough"). It can cause acute tracheobronchitis and, less commonly, pneumonia.
• Who's at risk: Dogs in high-density or social settings (kennels, shelters, dog daycares, dog shows, grooming facilities), unvaccinated dogs, puppies, elderly dogs, and dogs with other respiratory disease or immunosuppression.
• Typical prognosis: Most healthy dogs recover within 7–21 days with supportive care; dogs that develop secondary bacterial pneumonia or are immunocompromised may require prolonged treatment and hospitalization. Prognosis is generally good with prompt recognition and appropriate care.

Pathophysiology — explained simply

Bordetella bronchiseptica attaches to and inflames the lining of the nose, throat and trachea. It produces toxins and adhesins that interfere with normal mucociliary clearance (the mechanism that moves mucus and trapped particles out of the airways). This causes coughing, sneezing and increased mucus production. In healthy dogs the infection often remains confined to the upper airways (tracheobronchitis); in susceptible dogs it can progress to pneumonia when bacteria reach the lower airways or when the immune system is impaired.

B. bronchiseptica often acts alone or together with viruses (like canine parainfluenza, adenovirus-2, or canine influenza) — that combination is why the syndrome is called CIRDC or "kennel cough".

Breed-specific risk factors and prevalence

• Prevalence: Bordetella is one of the most commonly identified bacterial causes of CIRDC worldwide; prevalence varies by population but is high in shelter and kennel outbreaks.
• Breed-related risks: No breed has uniquely high innate susceptibility, but brachycephalic (short-nosed) breeds (e.g., Bulldogs, Pugs) and toy breeds are at higher risk of severe clinical disease because of conformational airway disease and reduced mucociliary clearance.
• Other risk factors: Puppies (immature immunity), geriatric dogs, dogs on immunosuppressive drugs (e.g., corticosteroids), and dogs with chronic airway disease (tracheal collapse, bronchiectasis) are at increased risk of prolonged or severe disease.

Typical clinical course and staging

• Incubation period: Usually 2–10 days after exposure.
• Early stage (days 1–3): mild nasal discharge, sneezing, low-grade fever possible, intermittent dry honking cough.
• Established upper airway disease (days 3–10): persistent dry or productive cough, gagging, retching, possible mucopurulent nasal discharge. Appetite usually maintained unless secondary illness.
• Complicated disease (if occurs): progression to lower airway infection (pneumonia) with lethargy, fever, increased respiratory rate/effort, cyanosis. This requires urgent care.
• Course: Uncomplicated cases often resolve in 7–21 days; cough can linger for several weeks even after recovery.

Symptoms — what owners typically see

• Sudden onset of a harsh, paroxysmal "honking" cough
• Sneezing and nasal discharge (clear to mucopurulent)
• Retching or gagging after coughing
• Reduced activity, mild fever (in some dogs)
• In severe cases: rapid respiratory rate, labored breathing, inappetence, depression

Diagnostic approach

Goal: identify whether Bordetella is present and whether lower airway disease (pneumonia) is present.

Always balance diagnostic invasiveness with clinical status — many uncomplicated cases are managed empirically.

When antibiotics are warranted (antibiotic stewardship)

B. bronchiseptica is a bacterial pathogen, but not all dogs with an acute cough need immediate antibiotics. Consider antibiotics when:

• There is evidence of bacterial infection: mucopurulent discharge, fever, worsening cough beyond 7–10 days, or clinical deterioration.
• Signs of lower respiratory tract involvement or pneumonia (increased respiratory rate, labored breathing, abnormal thoracic radiographs).
• Dogs at high risk of complications (puppies, geriatrics, immunocompromised) where early therapy may prevent progression.

• Doxycycline: commonly used; 5–10 mg/kg PO once to twice daily depending on formulation and GI tolerance. Typical adult dose: 5 mg/kg PO q12–24h (many clinicians use q12h).
• Amoxicillin-clavulanate (clavulanic acid): 12.5–20 mg/kg PO q8–12h (amoxicillin component). Good for many respiratory pathogens.
• Azithromycin: sometimes used for intracellular or atypical infections; dosing and duration vary — often 5–10 mg/kg PO once daily for 3–5 days followed by alternate-day dosing; use after consultation due to tissue accumulation and stewardship concerns.

• Avoid routine use of fluoroquinolones (e.g., enrofloxacin) as first-line unless supported by culture/sensitivity and risk/benefit analysis because of resistance concerns.
• Typical duration: uncomplicated upper airway disease — 7–14 days; pneumonia or complicated cases — often 3–6 weeks, guided by clinical response and radiographs.
• Adjust antibiotics based on culture & sensitivity when available.

Supportive and adjunctive treatment

• Cough suppressants (e.g., hydrocodone) only when cough is non-productive and interfering with rest; avoid if there is risk of aspiration or lower airway secretions.
• Nebulization and coupage to loosen secretions (especially useful in debilitated dogs or those with pneumonia).
• Intravenous fluids and oxygen therapy for hypoxemic dogs.
• Rest and reduced activity until improved.
• Avoid corticosteroids unless specifically indicated for severe inflammation and only under veterinary guidance (steroids can worsen some infections).

Vaccination: intranasal vs injectable

Bordetella vaccines are non-core but strongly recommended for dogs at increased risk of exposure.

General points

• Vaccination reduces clinical signs, shedding and duration of disease, but does not reliably prevent infection in all cases.
• Vaccination schedules and age limits vary by manufacturer — follow label instructions and your veterinarian's advice.

• Mechanism: stimulate local mucosal immunity (IgA) in the upper respiratory tract and reduce colonization and shedding.
• Onset: more rapid protection; some products claim onset of immunity within 72 hours to 7 days.
• Pros: faster onset, better mucosal immunity, decreased shedding; useful for immediate protection before kennel stays.
• Cons: may cause transient sneezing or mild nasal discharge soon after administration; handling live organisms requires following label precautions.

• Mechanism: generate systemic immunity (IgG), which can reduce disease severity but less effective at preventing colonization of mucosal surfaces compared with intranasal products.
• Onset: generally slower than intranasal.
• Pros: easy administration, no post-vaccinal sneezing.
• Cons: may be less effective at blocking shedding and colonization.

• For dogs going into boarding/daycare or exposed to congregate settings, intranasal vaccines are often preferred when rapid mucosal protection is needed (and when vaccine label permits). If a dog is nervous or there are local contraindications, injectable vaccines are an acceptable alternative.
• Booster frequency: many clinics recommend annual booster for dogs at risk; some settings use 6–12 monthly boosters depending on exposure risk and clinic policy. Check product labeling and clinic protocols.

(References: AAHA and WSAVA vaccination guidance recommend risk-based use of bordetella vaccines.)

Isolation period and contagion control

• Shedding: Dogs may shed B. bronchiseptica beginning in the incubation period and commonly for 1–3 weeks after onset; some dogs shed longer.
• Practical isolation guidance: keep affected dogs away from other dogs for at least 10–14 days from onset of clinical signs and until they have been clinically improved (no fever, decreased cough). For conservative control in kennels or shelters, isolate for up to 3 weeks or until PCR/culture is negative.
• In group settings: exclude affected dogs until asymptomatic for 48–72 hours and at least 10–14 days from onset; cohort exposed dogs and monitor closely.

Prevention in multi-dog environments (kennels, shelters, daycares)

Practical, evidence-based infection control measures:

• Vaccination policy: require/recommend bordetella vaccination (intranasal or injectable) for all dogs that attend daycare, boarding or grooming; maintain up-to-date records.
• Intake screening: ask about recent cough/exposure and defer admittance of dogs with respiratory signs.
• Quarantine new arrivals: isolate new dogs for 7–14 days when practical before mixing with resident groups.
• Cohorting: separate groups by age/health status; avoid mixing high-risk dogs with vulnerable populations (puppies, geriatrics).
• Environmental controls: improve ventilation, reduce overcrowding, clean and disinfect surfaces, bowls and crates with agents active against bacteria (follow product labels and contact times).
• Reduce fomite transmission: avoid sharing water bowls, toys and grooming equipment unless sanitized between uses.
• Staff training: educate staff to recognize early signs and to report coughs immediately.
• Record keeping: document vaccination, exposures and illness to support contact tracing.

Long-term management and monitoring

• For dogs recovering at home: monitor appetite, activity, coughing frequency and any new breathing difficulties.
• For recurrent or chronic cough (>4 weeks): investigate for underlying disease (chronic bronchitis, tracheal collapse, aspiration, foreign body, pulmonary disease) — referral to internal medicine may be indicated.
• Re-check radiographs if pneumonia was diagnosed to confirm resolution before discontinuing antibiotics for complicated cases.
• Maintain vaccination for dogs with ongoing exposure risk; discuss frequency with your veterinarian.

Prognosis and quality of life

• Uncomplicated tracheobronchitis caused by Bordetella generally carries an excellent prognosis. Most dogs return to normal activity and quality of life within weeks.
• Dogs that develop pneumonia or have underlying cardiac, pulmonary, or immune compromise may have a guarded prognosis and require intensive care.
• Long-term consequences are uncommon, but chronic bronchitis or recurrent lower airway disease can occur in predisposed animals.

Living With Bordetella — daily practical tips

• Keep the dog warm, quiet and rested; reduce excitement and exercise until cough improves.
• Humidified air (steamy bathroom sessions) and short nebulization sessions can ease expectoration.
• Ensure hydration and appetite; offer palatable, warm foods if appetite is reduced.
• Separate your dog from other dogs in the household or avoid contact with dogs outside the home until cleared by a veterinarian.
• Clean noses and discharge gently with a soft, damp cloth; wash hands after handling to reduce zoonotic risk (especially around immunocompromised people).
• Follow medication instructions exactly and finish prescribed antibiotic courses when recommended.

When to See Your Vet Urgently

Seek veterinary care immediately if your dog has any of the following:

• Rapid or labored breathing, blue/pale gums or tongue
• Marked lethargy, collapse or inability to rise
• High fever (>104°F / 40°C) or persistent fever despite therapy
• Persistent inappetence for >24–48 hours
• Coughing that worsens or is accompanied by bloody sputum

Key takeaways

• Bordetella bronchiseptica is a common bacterial contributor to kennel cough; spread is easy in social dog settings.
• Diagnosis is by history, exam and confirmation with PCR or culture when needed; chest films if pneumonia suspected.
• Antibiotics are indicated in suspected bacterial infections, high-risk patients or pneumonia — doxycycline and amoxicillin-clavulanate are common first-line options; steward antibiotics carefully.
• Intranasal vaccines provide faster mucosal protection and reduce shedding; injectables are an alternative. Vaccination is recommended for dogs at risk.
• Isolation and good biosecurity in multi-dog environments are essential to prevent outbreaks.

Selected references and guidance

• American Animal Hospital Association (AAHA) Canine Vaccination Guidelines
• World Small Animal Veterinary Association (WSAVA) vaccination guidance
• ACVIM consensus literature on canine infectious respiratory disease complex (CIRDC)
• Peer-reviewed clinical studies on Bordetella vaccine efficacy and PCR diagnosis

Frequently Asked Questions